Comparing Zepbound and Mounjaro with Ozempic and Wegovy for the Treatment of Obesity Zepbound and Mounjaro, compared with Ozempic and Wegovy, represent advanced options for the treatment of obesity
However, the copay or coinsurance amounts will vary
Key facts Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes only not weight loss
Specifically, NAD rejected Willows argument based on physician prescribing practices, stating that an experts conclusory statement or action is of little value and that expert opinions are most reliable when coupled with competent and reliable evidence demonstrating scientific consensus on an issue. NAD also found that studies referenced by Willow concerning the effectiveness of its products for weight loss only involved FDA-approved GLP-1 products and were insufficient to validate claims for compounded alternatives that differ in active pharmaceutical ingredient, formulation or method of administration. Therefore, NAD concluded that Willow did not establish a reasonable basis for its claims and recommended that Willow discontinue or modify its advertising
For health-minded consumers, its about trading up in various categories, shown in the bar chart